Literature DB >> 23578772

Aggressive therapy improves cirrhosis in glycogen storage disease type IX.

Laurie A Tsilianidis1, Laurie M Fiske, Sara Siegel, Chris Lumpkin, Kate Hoyt, Melissa Wasserstein, David A Weinstein.   

Abstract

Glycogen storage disease type IX (GSD IX) is described as a benign condition that often does not require treatment. Most patients with the disease are thought to outgrow the childhood manifestations, which include hepatomegaly, poor growth, and ketosis with or without hypoglycemia. Long term complications including fibrosis and cirrhosis have seldom been reported in the most common subtype, GSD IXα. We present two cases of children with GSD IXα who had fibrosis at the time of diagnosis in addition to the commonly reported disease manifestations. Structured therapy with frequent doses of uncooked cornstarch and protein supplementation was initiated, and both children responded with improved growth velocity, increased energy, decreased hepatomegaly and improved well-being. Additionally, radiographic features of fibrosis improved. We propose that GSD IXα is not a benign condition. Even in patients with a less severe presentation, consideration of a structured treatment regimen to improve quality of life appears warranted.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23578772      PMCID: PMC3672367          DOI: 10.1016/j.ymgme.2013.03.009

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  13 in total

1.  Glycogen storage disease type IX: novel PHKA2 missense mutation and cirrhosis.

Authors:  Abiodun O Johnson; Jennifer L Goldstein; Deeksha Bali
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-07       Impact factor: 2.839

2.  A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty.

Authors:  J S Finkelstein; A Klibanski; R M Neer
Journal:  J Clin Endocrinol Metab       Date:  1996-03       Impact factor: 5.958

3.  Natural history of hepatocellular adenoma formation in glycogen storage disease type I.

Authors:  David Q Wang; Laurie M Fiske; Caroline T Carreras; David A Weinstein
Journal:  J Pediatr       Date:  2011-04-09       Impact factor: 4.406

4.  X-chromosomal inheritance of liver glycogenosis with phosphorylase kinase deficiency.

Authors:  F Huijing; J Fernandes
Journal:  Am J Hum Genet       Date:  1969-05       Impact factor: 11.025

5.  Autosomal glycogenosis of liver and muscle due to phosphorylase kinase deficiency is caused by mutations in the phosphorylase kinase beta subunit (PHKB).

Authors:  B Burwinkel; A J Maichele; O Aagenaes; H D Bakker; A Lerner; Y S Shin; J A Strachan; M W Kilimann
Journal:  Hum Mol Genet       Date:  1997-07       Impact factor: 6.150

6.  Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease.

Authors:  David A Weinstein; Joseph I Wolfsdorf
Journal:  Eur J Pediatr       Date:  2002-07-31       Impact factor: 3.183

7.  Phosphorylase kinase of the liver: deficiency in a girl with increased hepatic glycogen.

Authors:  G Hug; W K Schubert; G Chuck
Journal:  Science       Date:  1966-09-23       Impact factor: 47.728

8.  Detection of PHKA2 gene mutation in four Japanese patients with hepatic phosphorylase kinase deficiency.

Authors:  Kyoko Ban; Kohachiro Sugiyama; Kenji Goto; Fumihiko Mizutani; Hajime Togari
Journal:  Tohoku J Exp Med       Date:  2003-05       Impact factor: 1.848

9.  Characteristic growth pattern in male X-linked phosphorylase-b kinase deficiency (GSD IX).

Authors:  H M Schippers; G P A Smit; J P Rake; G Visser
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

10.  Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition.

Authors:  Daniëlle H J Martens; Jan Peter Rake; Gerjan Navis; Vaclav Fidler; Catharina M L van Dael; G Peter A Smit
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-01       Impact factor: 8.237

View more
  23 in total

1.  Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy.

Authors:  Gyongyi O Okechuku; Lawrence R Shoemaker; Monika Dambska; Laurie M Brown; Justin Mathew; David A Weinstein
Journal:  J Inherit Metab Dis       Date:  2017-06-13       Impact factor: 4.982

2.  Dietary Management of the Glycogen Storage Diseases: Evolution of Treatment and Ongoing Controversies.

Authors:  Katalin M Ross; Iris A Ferrecchia; Kathryn R Dahlberg; Monika Dambska; Patrick T Ryan; David A Weinstein
Journal:  Adv Nutr       Date:  2020-03-01       Impact factor: 8.701

3.  Clinical and Molecular Variability in Patients with PHKA2 Variants and Liver Phosphorylase b Kinase Deficiency.

Authors:  Deeksha S Bali; Jennifer L Goldstein; Keri Fredrickson; Stephanie Austin; Surekha Pendyal; Catherine Rehder; Priya S Kishnani
Journal:  JIMD Rep       Date:  2017-03-12

4.  Variability of disease spectrum in children with liver phosphorylase kinase deficiency caused by mutations in the PHKG2 gene.

Authors:  Deeksha S Bali; Jennifer L Goldstein; Keri Fredrickson; Catherine Rehder; Anne Boney; Stephanie Austin; David A Weinstein; Richard Lutz; Avihu Boneh; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2013-12-19       Impact factor: 4.797

5.  Chronic liver disease and impaired hepatic glycogen metabolism in argininosuccinate lyase deficiency.

Authors:  Lindsay C Burrage; Simran Madan; Xiaohui Li; Saima Ali; Mahmoud Mohammad; Bridget M Stroup; Ming-Ming Jiang; Racel Cela; Terry Bertin; Zixue Jin; Jian Dai; Danielle Guffey; Milton Finegold; Sandesh Nagamani; Charles G Minard; Juan Marini; Prakash Masand; Deborah Schady; Benjamin L Shneider; Daniel H Leung; Deeksha Bali; Brendan Lee
Journal:  JCI Insight       Date:  2020-02-27

6.  Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease Type I.

Authors:  Katalin M Ross; Laurie M Brown; Michelle M Corrado; Tayoot Chengsupanimit; Latravia M Curry; Iris A Ferrecchia; Laura Y Porras; Justin T Mathew; David A Weinstein
Journal:  JIMD Rep       Date:  2015-08-25

Review 7.  Dietary management in glycogen storage disease type III: what is the evidence?

Authors:  Terry G J Derks; G Peter A Smit
Journal:  J Inherit Metab Dis       Date:  2014-08-28       Impact factor: 4.982

Review 8.  Investigation and management of the hepatic glycogen storage diseases.

Authors:  Kaustuv Bhattacharya
Journal:  Transl Pediatr       Date:  2015-07

9.  Evaluation of glycogen storage disease as a cause of ketotic hypoglycemia in children.

Authors:  Laurie M Brown; Michelle M Corrado; Rixt M van der Ende; Terry G J Derks; Margaret A Chen; Sara Siegel; Kate Hoyt; Catherine E Correia; Christopher Lumpkin; Theresa B Flanagan; Caroline T Carreras; David A Weinstein
Journal:  J Inherit Metab Dis       Date:  2014-07-29       Impact factor: 4.982

10.  Fatty Liver Caused by Glycogen Storage Disease Type IX: A Small Series of Cases in Children.

Authors:  Catarina Leuzinger Dias; Inês Maio; José Ricardo Brandão; Edite Tomás; Esmeralda Martins; Ermelinda Santos Silva
Journal:  GE Port J Gastroenterol       Date:  2019-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.